Maze Therapeutics (MAZE) insider exercises 7,500 options, sells 7,500 shares
Rhea-AI Filing Summary
Maze Therapeutics, Inc. officer Atul Dandekar reported exercising stock options for 7,500 shares of common stock at an exercise price of $10.42 per share and selling 7,500 shares of common stock in multiple transactions at weighted-average prices of $27.3064 and $27.89. These transactions were effected under a Rule 10b5-1 trading plan adopted on September 29, 2025. The fully vested option, which expires on April 11, 2031, left 21,643 options outstanding after the exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($127K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Dandekar Atul
Role
CSBO
Sold
7,500 shs ($205K)
Approx. gross sale proceeds
$205K
Approx. exercise cost
$78K
Approx. pre-tax spread
$127K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F4 | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,500 | $10.42 | $78K |
| Sale | Common Stock F1, F2 | 7,100 | $27.3064 | $194K |
| Sale | Common Stock F1, F3 | 400 | $27.89 | $11K |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,643 shares (Direct);
Common Stock — 26,250 shares (Direct)
Footnotes (4)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $27.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.81 to $27.96 per share, inclusive.
- F4. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
Key Figures
Options exercised into shares: 7,500 shares
Option exercise price: $10.42 per share
Shares sold tranche 1: 7,100 shares
+5 more
8 metrics
Options exercised into shares
7,500 shares
Stock options exercised into common stock on July 29, 2026
Option exercise price
$10.42 per share
Exercise or conversion price of the stock option
Shares sold tranche 1
7,100 shares
Common stock sold at weighted-average $27.3064 on July 29, 2026
Sale price tranche 1
$27.3064 per share
Weighted-average sale price; individual trades from $26.81 to $27.79
Shares sold tranche 2
400 shares
Common stock sold at weighted-average $27.89 on July 29, 2026
Sale price tranche 2
$27.89 per share
Weighted-average sale price; trades from $27.81 to $27.96
Remaining stock options
21,643 options
Stock options remaining after the reported 7,500-share exercise
Rule 10b5-1 plan adoption date
September 29, 2025
Date the reporting person adopted the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), fully vested
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
fully vested financial
"The option is fully vested. Pursuant to the terms of the reporting person's award"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transactions did Atul Dandekar report for Maze Therapeutics (MAZE)?
Atul Dandekar reported exercising 7,500 stock options at $10.42 per share and acquiring the same number of Maze Therapeutics common shares, then selling 7,500 shares in multiple transactions at weighted-average prices of $27.3064 and $27.89 on July 29, 2026.
Were Maze Therapeutics (MAZE) trades by Atul Dandekar made under a Rule 10b5-1 plan?
Yes. The transactions were effected under a Rule 10b5-1 trading plan adopted by Atul Dandekar on September 29, 2025, indicating the trades followed a pre-arranged plan rather than discretionary timing.
How many Maze Therapeutics (MAZE) options does Atul Dandekar retain after these transactions?
After exercising 7,500 options, Atul Dandekar is reported to hold 21,643 stock options in Maze Therapeutics. The option is fully vested and is scheduled to expire on April 11, 2031.
What kind of derivative security did Atul Dandekar exercise at Maze Therapeutics (MAZE)?
He exercised a Stock Option (Right to Buy) covering 7,500 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share, converting it into common shares before selling an equivalent number of shares.